MAP2K1 E203K

CI-VAR-00000697Explore in graph →NP_002746.1:p.Glu203LysNM_002755.3:c.607G>AClinVar 375982 CIViC 1626

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma1
MAP2K1 E203K	Vemurafenib	Predictive	C	Supports Resistance	—	submitted	EID4728 In a retrospective study, of a phase 2 clinical trial (NCT00949702), of 132 BRAF mutation positive metastatic melanoma patients treated with vemurafenib monotherapy, the MAP2K1 E203K mutation was asso… (full text at CIViC) PMID 23569304 · Trunzer et al., 2013 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.